Active Ingredient History

  • Now
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.   Wikipedia

More Chemistry
a-796874.0 | abt-874 | briakinumab | bsf-415977 | j695 | j-695 | lu-415977 | ozespa | way-165772


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue